Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T18:31:46.752Z.
Calculation as of: 2026-10-06T18:31:46.752Z.
Quote observation: 2026-10-06T18:30:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 243952859d49b374df7eb324c8bbcd7e4caeb894f26e22f2834818a88b726353
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$1.85B
EV/EBITDA Ratio
13.55x
TTM Avg
17.09x
3Y Avg
17.06x
5Y Avg
16.05x
Market Cap
$1.87B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.82B
EV/EBITDA Ratio
N/A
TTM Avg
349.46x
3Y Avg
208.93x
5Y Avg
208.93x
Market Cap
$1.82B
EV/EBITDA Ratio
21.82x
TTM Avg
30.23x
3Y Avg
32.57x
5Y Avg
30.28x
Market Cap
$1.89B
EV/EBITDA Ratio
170.26x
TTM Avg
162.32x
3Y Avg
213.45x
5Y Avg
213.45x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunome, Inc. (IMNM) | $1.86B | N/A | N/A | N/A | N/A |
| Astrana Health, Inc. (ASTH)vs › | $1.85B | 13.55x | 17.09x | 17.06x | 16.05x |
| Azenta, Inc. (AZTA)vs › | $1.84B | 49.83x | 24.79x | 97.87x | 107.08x |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.87B | N/A | N/A | N/A | N/A |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.82B | N/A | 349.46x | 208.93x | 208.93x |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.82B | 21.82x | 30.23x | 32.57x | 30.28x |
| Xencor, Inc. (XNCR)vs › | $1.82B | N/A | 26.29x | 37.47x | 47.79x |
| Trevi Therapeutics, Inc. (TRVI)vs › | $1.89B | N/A | N/A | N/A | N/A |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 170.26x | 162.32x | 213.45x | 213.45x |
| Novavax, Inc. (NVAX)vs › | $1.81B | N/A | 3.29x | 3.29x | 3.29x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
